Robert Nussenblatt

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Overexpression of IL-17RC associated with ocular sarcoidosis
    Wenting Wu
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Transl Med 12:152. 2014
  2. pmc Immune Responses in Age-Related Macular Degeneration and a Possible Long-term Therapeutic Strategy for Prevention
    Robert B Nussenblatt
    National Eye Institute, National Institutes of Health, Bethesda, Maryland Electronic address
    Am J Ophthalmol 158:5-11.e2. 2014
  3. pmc Pro-angiogenic effect of IFNgamma is dependent on the PI3K/mTOR/translational pathway in human retinal pigmented epithelial cells
    Baoying Liu
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Mol Vis 16:184-93. 2010
  4. pmc The Chinese medicine formula HB01 reduces choroidal neovascularization by regulating the expression of vascular endothelial growth factor
    Ming Jin
    Department of Ophthalmology, China Japan Friendship Hospital, Beijing University of Chinese Medicine, Beijing, China
    J Transl Med 10:118. 2012
  5. pmc OX40 ligand expression abrogates the immunosuppressive function of retinal pigment epithelium
    Matthew A Cunningham
    Vitreoretinal Service, Department of Ophthalmology and Visual Sciences, The University of Iowa Hospitals and Clinics, Iowa City, IA, 52242, USA
    J Ophthalmic Inflamm Infect 3:12. 2013
  6. pmc A rare case of endogenous Aspergillus conicus endophthalmitis in an immunocompromised patient
    Wendy M Smith
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, 10 Center Dr, 10 10N112, Bethesda, MD, 20892, USA
    J Ophthalmic Inflamm Infect 3:37. 2013
  7. doi request reprint The immunological basis of degenerative diseases of the eye
    Robert B Nussenblatt
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20814, USA
    Int Rev Immunol 32:97-112. 2013
  8. pmc Complement component C5a promotes expression of IL-22 and IL-17 from human T cells and its implication in age-related macular degeneration
    Baoying Liu
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Transl Med 9:1-12. 2011
  9. pmc A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization
    Robert B Nussenblatt
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Retina 30:1579-87. 2010
  10. doi request reprint National Institutes of Health Center for Human Immunology Conference, September 2009
    Robert B Nussenblatt
    Laboratory of Immunology, National Eye Institute, Maryland 20892, USA
    Ann N Y Acad Sci 1200:E1-23. 2010

Collaborators

Detail Information

Publications33

  1. pmc Overexpression of IL-17RC associated with ocular sarcoidosis
    Wenting Wu
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Transl Med 12:152. 2014
    ..Sarcoidosis is a chronic inflammatory disease with a systemic granulomatous disorder affecting multiple organs including the eye. Both CD4+ T cell and macrophage have been linked to the pathogenesis of the disease...
  2. pmc Immune Responses in Age-Related Macular Degeneration and a Possible Long-term Therapeutic Strategy for Prevention
    Robert B Nussenblatt
    National Eye Institute, National Institutes of Health, Bethesda, Maryland Electronic address
    Am J Ophthalmol 158:5-11.e2. 2014
    ..To describe the immune alterations associated with age-related macular degeneration (AMD); and, based on these findings, to offer an approach to possibly prevent the expression of late disease...
  3. pmc Pro-angiogenic effect of IFNgamma is dependent on the PI3K/mTOR/translational pathway in human retinal pigmented epithelial cells
    Baoying Liu
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Mol Vis 16:184-93. 2010
    ....
  4. pmc The Chinese medicine formula HB01 reduces choroidal neovascularization by regulating the expression of vascular endothelial growth factor
    Ming Jin
    Department of Ophthalmology, China Japan Friendship Hospital, Beijing University of Chinese Medicine, Beijing, China
    J Transl Med 10:118. 2012
    ..Currently anti-vascular endothelial growth factor (VEGF) therapies are broadly used to treat neovascular ocular disorders. Here we demonstrate the effect of a traditional Chinese medicine formula, HB01, on CNV...
  5. pmc OX40 ligand expression abrogates the immunosuppressive function of retinal pigment epithelium
    Matthew A Cunningham
    Vitreoretinal Service, Department of Ophthalmology and Visual Sciences, The University of Iowa Hospitals and Clinics, Iowa City, IA, 52242, USA
    J Ophthalmic Inflamm Infect 3:12. 2013
    ..Peripheral blood mononuclear cells (PBMCs) were isolated from healthy human donors. Human ARPE cells (±OX40L ± GITR ligand (GITRL) expression) and PBMCs were co-cultured for in vitro proliferation studies...
  6. pmc A rare case of endogenous Aspergillus conicus endophthalmitis in an immunocompromised patient
    Wendy M Smith
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, 10 Center Dr, 10 10N112, Bethesda, MD, 20892, USA
    J Ophthalmic Inflamm Infect 3:37. 2013
    ..He had bilateral anterior uveitis, granulomatous vitritis with a preretinal granuloma in the right eye, and nongranulomatous vitritis with two quadrants of chorioretinal scarring in the left...
  7. doi request reprint The immunological basis of degenerative diseases of the eye
    Robert B Nussenblatt
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20814, USA
    Int Rev Immunol 32:97-112. 2013
    ..Immune mediation has been shown to be a part of many of the most common ocular disorders, and not just that of uveitis, or ocular inflammatory disease...
  8. pmc Complement component C5a promotes expression of IL-22 and IL-17 from human T cells and its implication in age-related macular degeneration
    Baoying Liu
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Transl Med 9:1-12. 2011
    ..Elevated levels of complement activating molecules including complement component 5a (C5a) have been found in the serum of AMD patients. Our aim is to study whether C5a can impact human T cells and its implication in AMD...
  9. pmc A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization
    Robert B Nussenblatt
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Retina 30:1579-87. 2010
    ..We compared anti-VEGF therapy plus one of three systemic immunosuppressive therapies versus anti-VEGF therapy alone for recurrent choroidal neovascularization associated with age-related macular degeneration...
  10. doi request reprint National Institutes of Health Center for Human Immunology Conference, September 2009
    Robert B Nussenblatt
    Laboratory of Immunology, National Eye Institute, Maryland 20892, USA
    Ann N Y Acad Sci 1200:E1-23. 2010
    ..The human immunology meeting was held in the Clinical Center of the National Institutes of Health, Bethesda, Maryland, on September 3 and 4, 2009...
  11. pmc The status of clinical trials: cause for concern
    Robert B Nussenblatt
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Building 10, Room 10N112, 10 Center Drive, Bethesda, MD 20892, USA
    J Transl Med 8:65. 2010
    ..Americans see clinical research as important, with over 15 million American residents participating in NIH-sponsored studies in 2008 and growing yearly...
  12. doi request reprint C5a contributes to intraocular inflammation by affecting retinal pigment epithelial cells and immune cells
    Mengjun Hu
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA
    Br J Ophthalmol 95:1738-44. 2011
    ..In this study, the authors sought to investigate C5a's effects on human retinal pigment epithelial (RPE) cells and peripheral blood mononuclear cells (PBMCs), and on the interaction between RPE cells and PBMCs...
  13. ncbi request reprint Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration
    Robert B Nussenblatt
    The National Eye Institute, Laboratory of Immunology, NIH, Building 10, 10 Center Drive, Bethesda, MD, USA
    J Autoimmun 21:283-93. 2003
    ..These studies suggest that anti-IL-2 receptor blockade could be useful in the treatment of Th1-mediated autoimmune conditions...
  14. ncbi request reprint Vitamin E in the treatment of uveitis-associated macular edema
    Robert B Nussenblatt
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Building 10, Rm 10S219, 10 Center Drive, Bethesda, MD 20892, USA
    Am J Ophthalmol 141:193-4. 2006
    ..To investigate whether high-dose alpha-tocopherol (vitamin E) could reduce vision loss and retinal thickening associated with uveitis-associated cystoid macular edema...
  15. pmc Age-related macular degeneration and the immune response: implications for therapy
    Robert B Nussenblatt
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Ophthalmol 144:618-26. 2007
    ..To review the available information concerning the immune mediation of age-related macular degeneration (AMD) and to speculate on proposed mechanisms and immunotherapy...
  16. pmc Biologically active fibronectin fragments stimulate release of MCP-1 and catabolic cytokines from murine retinal pigment epithelium
    Bobbie Ann Austin
    National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892 1857, USA
    Invest Ophthalmol Vis Sci 50:2896-902. 2009
    ..The purpose of the study was to determine whether Fnfs stimulate the release of proinflammatory and catabolic cytokines from murine retinal pigment epithelium (RPE)...
  17. ncbi request reprint Age-related macular degeneration: an immunologically driven disease
    Robert B Nussenblatt
    National Institutes of Health, National Eye Institute, Laboratory of Immunology, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Curr Opin Investig Drugs 10:434-42. 2009
    ..A working hypothesis is also presented that may reconcile the current understanding of the pathogenesis of AMD and some apparently contradictory findings in the literature...
  18. pmc Translational medicine--doing it backwards
    Robert B Nussenblatt
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Transl Med 8:12. 2010
    ..Its mission is science in pursuit of fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to extend healthy life and reduce the burdens of illness and disability 1...
  19. ncbi request reprint Orally and nasally induced tolerance studies in ocular inflammatory disease: guidance for future interventions
    Robert Nussenblatt
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bldg 10, Room 10S219, 10 Center Drive, Bethesda, MD 20892, USA
    Ann N Y Acad Sci 1029:278-85. 2004
    ..This review will deal with animal and human studies in the treatment of ocular inflammatory disease with the goal of extracting from past experience how to construct a future study in humans...
  20. pmc International Central Nervous System and Ocular Lymphoma Workshop: recommendations for the future
    Robert B Nussenblatt
    Laboratory of Immunology, National Eye Institute, NIH, 10 Center Drive, Building 10, Room 10S219, Bethesda, MD, 20892, USA
    Ocul Immunol Inflamm 14:139-44. 2006
    ..To bring together multidisciplinary experts to discuss primary central nervous system lymphoma (PCNSL) and primary intraocular lymphoma (PIOL)...
  21. ncbi request reprint Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration
    Monica Dalal
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA
    Graefes Arch Clin Exp Ophthalmol 251:2705-9. 2013
    ..This small short-term pilot study assesses the safety of subconjunctival Palomid 529 in the treatment of neovascular AMD, with some limited efficacy information...
  22. pmc Subconjunctival sirolimus in the treatment of diabetic macular edema
    Nupura Krishnadev
    National Eye Institute, National Institutes of Health, Bethesda, MD, 20892, USA
    Graefes Arch Clin Exp Ophthalmol 249:1627-33. 2011
    ..This phase I/II study assesses the safety of multiple subconjunctival sirolimus injections for the treatment of DME, with some limited efficacy data...
  23. pmc Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease
    Keith Wroblewski
    Laboratory of Immunology, National Institutes of Health, Bethesda, MD, USA
    Can J Ophthalmol 46:322-8. 2011
    ..Safety and efficacy of daclizumab during an 11-year period...
  24. ncbi request reprint Diagnostic procedures in vitreoretinal lymphoma
    Monica Dalal
    National Eye Institute, National Institutes of Health, Bethesda, United States
    Ocul Immunol Inflamm 22:270-6. 2014
    ..9 months. Conclusion: Vitreoretinal lymphoma is difficult to recognize and requires a high degree of clinical suspicion. It often takes more than one invasive procedure to make the diagnosis. ..
  25. pmc Comparison of wide-field fluorescein angiography and 9-field montage angiography in uveitis
    Benjamin P Nicholson
    National Eye Institute, National Institutes of Health, Bethesda, MD
    Am J Ophthalmol 157:673-7. 2014
    ..We hypothesized that Optos images reveal more leakage in patients with uveitis...
  26. doi request reprint Susceptibility genes and pharmacogenetics in ocular inflammatory disorders
    Baoying Liu
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Ocul Immunol Inflamm 20:315-23. 2012
    ..They propose polygenic and composite models of treatment responses to fulfill individualized drug therapy in intraocular inflammatory disorders...
  27. pmc Orbital lymphoma masquerading as panuveitis
    Puneet Panda
    National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA
    Ocul Immunol Inflamm 18:181-3. 2010
    ..To describe a case of orbital mucosa-associated lymphoid tissue (MALT) lymphoma masquerading as unilateral panuveitis...
  28. doi request reprint Fundus autofluorescence patterns in primary intraocular lymphoma
    Megan Casady
    National Eye Institute, National Institutes of Health, Bethesda, Maryland and Associated Retinal Consultants, P C, Royal Oak, Michigan
    Retina 34:366-72. 2014
    ..To evaluate fundus autofluorescence (FAF) patterns in patients with primary intraocular (vitreoretinal) lymphoma...
  29. pmc Ophthalmic manifestations, cytology, immunohistochemistry, and molecular analysis of intraocular metastatic T-cell lymphoma: report of a case and review of the literature
    Grace A Levy-Clarke
    National Eye Institute, National Institutes of Health, Bethesda, MD, USA
    Surv Ophthalmol 53:285-95. 2008
    ....
  30. doi request reprint The National Institutes of Health Center for Human Immunology, Autoimmunity, and Inflammation: history and progress
    Howard B Dickler
    Center for Human Immunology, National Institutes of Health, Bethesda, MD 20892, USA
    Ann N Y Acad Sci 1285:133-47. 2013
    ..Challenges, opportunities, and progress are detailed...
  31. ncbi request reprint A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy
    John C Morris
    Metabolism Branch, Laboratory of Pathology, Department of Laboratory Medicine, National Eye Institute, Bethesda, MD 20892 1457, USA
    Clin Cancer Res 13:958-64. 2007
    ..The primary end point was to determine drug toxicity. Tumor response, tumor-specific CD8+ T-cell immune responses, and modulation of CD4+ CD25+ FoxP3+ regulatory T-cell (Treg) numbers were secondary end points...
  32. pmc Primary intraocular lymphoma: diagnosis and differential diagnosis
    H Nida Sen
    National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Ocul Immunol Inflamm 17:133-41. 2009
    ..In addition to cytology, flow cytometry, immunohistochemistry, molecular analysis and cytokines may be used as adjuncts in facilitating the diagnosis...
  33. pmc PDGF-CC blockade inhibits pathological angiogenesis by acting on multiple cellular and molecular targets
    Xu Hou
    National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:12216-21. 2010
    ..Thus, we identified PDGF-CC as an important candidate target gene for antiangiogenic therapy, and PDGF-CC inhibition may be of therapeutic value in treating neovascular diseases...